agilon health, inc. (NYSE:AGL – Get Free Report) CEO Steven Sell acquired 20,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $3.36 per share, for a total transaction of $67,200.00. Following the completion of the purchase, the chief executive officer now owns 67,590 shares in the company, valued at approximately $227,102.40. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
agilon health Stock Performance
AGL stock opened at $4.00 on Thursday. The stock has a market capitalization of $1.65 billion, a PE ratio of -5.71 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.36 and a quick ratio of 1.36. The company has a 50 day moving average price of $5.26 and a 200 day moving average price of $5.55. agilon health, inc. has a fifty-two week low of $3.07 and a fifty-two week high of $20.37.
agilon health (NYSE:AGL – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.56 billion. agilon health had a negative return on equity of 29.91% and a negative net margin of 5.57%. The firm’s quarterly revenue was up 38.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) earnings per share. Analysts forecast that agilon health, inc. will post -0.32 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of analysts have weighed in on AGL shares. Evercore ISI upped their price target on agilon health from $5.50 to $7.00 and gave the company an “in-line” rating in a research report on Tuesday, July 9th. Baird R W upgraded shares of agilon health to a “hold” rating in a research report on Thursday, May 30th. Benchmark restated a “buy” rating and issued a $9.00 price target on shares of agilon health in a research report on Thursday, August 8th. Robert W. Baird initiated coverage on shares of agilon health in a research note on Thursday, May 30th. They set a “neutral” rating and a $6.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of agilon health from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.57.
Get Our Latest Stock Report on agilon health
About agilon health
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Read More
- Five stocks we like better than agilon health
- Trading Stocks: RSI and Why it’s Useful
- How Much Can You Make in Stocks in One Month?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- Using the MarketBeat Stock Split Calculator
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.